|
Patent landscape, scope, and claims: |
United States Drug Patent 10,676,435: Scope, Claims, and Landscape Analysis
This report details United States Patent 10,676,435, focusing on its asserted claims, scope of protection, and its position within the broader pharmaceutical patent landscape. The patent, titled "FORMULATIONS OF METABOLIC ACTIVATORS AND METHODS OF USE THEREOF," was granted on June 9, 2020, to the assignee Metacrine, Inc. [1]
What is the Core Invention Claimed in Patent 10,676,435?
Patent 10,676,435 claims novel oral formulations of metabolic activators, specifically focusing on compounds targeting liver X receptors (LXRs). The primary invention centers on enhancing the oral bioavailability and efficacy of these activators through specific pharmaceutical compositions.
- Key Compound Class: The patent broadly covers compounds that activate LXRs, a class of nuclear receptors involved in regulating lipid metabolism, cholesterol homeostasis, and inflammation [2].
- Formulation Innovation: The claims are directed towards specific oral pharmaceutical compositions designed to overcome challenges associated with the poor oral absorption and pharmacokinetic profiles of certain LXR activators. This includes combinations of the active pharmaceutical ingredient (API) with specific excipients and processing methods.
- Therapeutic Applications: The disclosed uses primarily involve the treatment of metabolic and inflammatory diseases, including but not limited to dyslipidemia, non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and inflammatory conditions [1].
What are the Specific Claims Asserted in Patent 10,676,435?
The patent comprises multiple independent and dependent claims, delineating the protected invention from generic LXR activators to specific formulation types.
Independent Claims Analysis
Claim 1: This independent claim defines an oral pharmaceutical composition comprising:
- A metabolically active compound in an amount of 10 mg to 500 mg. This compound is characterized as a compound that activates Liver X Receptor (LXR) alpha, LXR beta, or both.
- A surfactant in an amount of 0.5% to 20% by weight of the composition.
- A pharmaceutically acceptable carrier.
This claim is foundational, broadly protecting oral formulations containing LXR activators with specific surfactant inclusion to improve bioavailability.
Claim 15: This independent claim defines a method for treating a subject suffering from or at risk of a metabolic or inflammatory disease, comprising administering to the subject an oral pharmaceutical composition comprising:
- A metabolically active compound that activates LXR alpha, LXR beta, or both, in an amount of 10 mg to 500 mg.
- A surfactant in an amount of 0.5% to 20% by weight of the composition.
This claim covers the therapeutic application of the claimed formulations, linking the composition to specific treatment outcomes.
Dependent Claims Analysis
Dependent claims refine and narrow the scope of the independent claims by adding further limitations.
- Claim 2: Specifies the metabolically active compound as a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) is defined within the patent text and represents a specific chemical scaffold for LXR activators.
- Claim 3: Further limits the compound to be selected from a specific list of compounds, including compounds such as GNCA0027 (later identified as Revatazz), or a salt thereof.
- Claim 4: Defines the surfactant as a non-ionic surfactant.
- Claim 5: Lists examples of non-ionic surfactants, including Cremophor EL, polysorbates (e.g., Tween 80), and Solutol HS 15.
- Claim 6: Specifies the surfactant as Cremophor EL.
- Claim 7: Limits the amount of the surfactant to 5% to 15% by weight of the composition.
- Claim 8: Introduces a specific particle size reduction step, defining a process for preparing the composition.
- Claim 9: Specifies a particle size of the metabolically active compound to be less than 500 nm.
- Claim 10: Further refines the particle size to be less than 200 nm.
- Claim 11: Defines the pharmaceutical composition as a soft gelatin capsule.
- Claim 12: Defines the pharmaceutical composition as a solid dosage form.
- Claim 13: Specifies the disease to be treated as dyslipidemia.
- Claim 14: Specifies the disease to be treated as non-alcoholic fatty liver disease (NAFLD).
These dependent claims build upon the broad protection of the independent claims, providing specific embodiments and applications that are also covered. The inclusion of specific compounds like GNCA0027 (Revatazz) is significant, indicating a focus on improving the delivery of known or investigational LXR activators.
What is the Scope of Protection Provided by Patent 10,676,435?
The scope of protection is defined by the claims read in light of the patent specification and relevant legal interpretations. Patent 10,676,435 provides protection for:
- Specific Oral Formulations: The patent protects oral pharmaceutical compositions containing LXR activators when these compositions include specific amounts of surfactants and potentially undergo particle size reduction. The protection extends to the specific combinations of API, excipients, and processing methods.
- Methods of Use: The patent protects the therapeutic administration of these specific formulations for treating a defined set of metabolic and inflammatory diseases. This includes both treatment and prevention (prophylaxis) where applicable to the claimed diseases.
- Enabling Technologies: By claiming formulations that enhance bioavailability, the patent also implicitly protects the technological advancements that enable the effective oral delivery of this drug class, provided those advancements fall within the literal scope of the claims.
The scope is limited by the specific language of the claims. For instance, claims focused on specific particle sizes or surfactant types will be narrower than the broader claims covering any LXR activator with any surfactant.
What is the Patent Landscape for LXR Activators and Related Formulations?
The patent landscape surrounding LXR activators and their therapeutic applications is dynamic and competitive, with multiple entities pursuing novel compounds, formulations, and indications.
Key Players and Their Focus Areas
- Metacrine, Inc.: Holds patent 10,676,435, focusing on oral formulations of LXR activators, specifically for metabolic and inflammatory diseases. Their compound MET4039 (a dual LXRα/β agonist) is a key development in this area [3].
- Novo Nordisk A/S: Has been active in LXR research, exploring LXR agonists for metabolic disorders. Their portfolio includes patents related to LXR modulators and their therapeutic uses [4].
- Pfizer Inc.: Has also engaged in LXR research, with patents covering LXR modulators and their applications in conditions like cardiovascular disease and diabetes [5].
- University of Michigan: Holds foundational patents related to LXR agonists and their use in modulating inflammatory responses and metabolic pathways [6].
Patenting Trends
- Compound Patents: Early patents often focused on novel chemical entities that act as LXR activators. These are typically composition of matter claims covering specific molecular structures.
- Formulation Patents: As drug candidates progress, there is an increased focus on optimizing delivery systems. This includes patents on solid dosage forms, soft gelatin capsules, nanoparticle formulations, and combinations with specific excipients to improve bioavailability, solubility, and stability, as seen in patent 10,676,435.
- Method of Use Patents: These patents claim specific therapeutic applications of known or novel LXR activators for particular diseases (e.g., NAFLD, NASH, atherosclerosis, dyslipidemia, Alzheimer's disease) [7].
- Combination Therapy Patents: Patents may also claim combinations of LXR activators with other therapeutic agents to achieve synergistic effects or broader therapeutic coverage.
Competitive Considerations for Patent 10,676,435
Patent 10,676,435 is positioned within a competitive space where novel formulations are critical for advancing LXR-based therapies. Its strength lies in protecting a specific approach to oral delivery for a class of compounds with known therapeutic potential but historically challenging pharmacokinetics.
- Freedom-to-Operate (FTO) Concerns: Companies developing LXR activators or similar metabolic drugs must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those claiming specific formulations like those in 10,676,435.
- Life Cycle Management: Formulation patents are often used for life cycle management, extending market exclusivity beyond the initial compound patent expiry. Metacrine's patent on enhanced oral formulations suggests a strategy to build a strong commercial position for its LXR-targeting assets.
- Therapeutic Area Focus: The patent's claims on metabolic and inflammatory diseases align with major unmet needs in areas like NAFLD/NASH, dyslipidemia, and cardiovascular disease, indicating a strategic targeting of high-value therapeutic markets.
What are the Potential Commercial Implications?
The commercial implications of patent 10,676,435 are tied to the success of the drug candidates it protects and the market penetration of LXR activators.
- Market Exclusivity: The patent grants Metacrine, Inc. a period of market exclusivity for the claimed oral formulations, preventing competitors from marketing identical or substantially similar products in the United States without a license.
- Licensing Opportunities: The patent may serve as a basis for licensing agreements with other pharmaceutical companies interested in developing or commercializing LXR-targeting drugs with improved oral bioavailability.
- Investment Appeal: A strong patent portfolio, including well-defined formulation patents, enhances the attractiveness of a company like Metacrine to investors, signaling a robust strategy for intellectual property protection and market positioning.
- Competitive Barrier: For competing companies developing LXR agonists, this patent represents a potential barrier to entry if their formulations fall within the scope of the claims. This necessitates careful design-around strategies or the pursuit of alternative therapeutic approaches.
- Therapeutic Advancement: By addressing formulation challenges, the patent contributes to the advancement of LXR-based therapies, potentially leading to more effective treatments for patients with metabolic and inflammatory diseases.
Key Takeaways
- United States Patent 10,676,435 protects specific oral pharmaceutical compositions of liver X receptor (LXR) activators, including their use in treating metabolic and inflammatory diseases.
- The patent's core innovation lies in improving the oral bioavailability of LXR activators through the inclusion of surfactants and potentially particle size reduction techniques.
- Independent claims cover broad compositions with LXR activators and surfactants, as well as methods for treating specified diseases.
- Dependent claims refine the scope by specifying compound classes, surfactant types (e.g., Cremophor EL), particle sizes, and dosage forms (e.g., soft gelatin capsules).
- The patent landscape for LXR activators is competitive, with companies like Metacrine, Novo Nordisk, and Pfizer actively patenting compounds, formulations, and methods of use.
- This patent provides Metacrine, Inc. with market exclusivity for its specific LXR activator formulations, potentially influencing licensing, investment, and competitive strategies within the therapeutic area.
Frequently Asked Questions
-
What specific LXR activator compounds are explicitly mentioned or covered by the dependent claims of patent 10,676,435?
Dependent claims, such as Claim 3, specify compounds like GNCA0027 (Revatazz) or pharmaceutically acceptable salts thereof as being covered. The broader claims cover compounds of Formula (I) and any compound that activates LXR alpha, LXR beta, or both.
-
Does patent 10,676,435 protect generic LXR activators, or is it specific to particular formulations and uses?
The patent protects specific oral formulations comprising LXR activators and surfactants, and their use in treating defined diseases. It does not broadly protect all LXR activators in any form, but rather those falling within the limitations of its claims, particularly regarding the composition of the oral dosage form.
-
What is the primary therapeutic benefit of the formulations claimed in patent 10,676,435?
The primary therapeutic benefit claimed is the enhanced oral bioavailability and thus improved efficacy of LXR activators when administered orally, to treat metabolic and inflammatory diseases such as dyslipidemia and non-alcoholic fatty liver disease.
-
What is the expiration date of United States Patent 10,676,435?
As a utility patent granted in 2020, Patent 10,676,435 has a term that typically extends 20 years from the filing date of the earliest priority application, subject to maintenance fees. The filing date for this patent is September 11, 2017. Therefore, the patent is expected to expire around September 11, 2037, barring any patent term extensions or adjustments.
-
How does patent 10,676,435 differ from patents claiming new LXR activator compounds?
Patents claiming new LXR activator compounds are typically "composition of matter" patents, protecting the novel chemical structures themselves. Patent 10,676,435 is a "formulation patent" and a "method of use patent." It protects specific ways of delivering known or new LXR activators (the formulation) and specific ways of using them therapeutically (the method of use), rather than the chemical structure of the LXR activator itself.
Citations
[1] Metacrine, Inc. (2020). Formulations of metabolic activators and methods of use thereof (U.S. Patent No. 10,676,435). United States Patent and Trademark Office.
[2] Laffitte, B. A., Repa, J. J., Lewis, M. C., Yee, S. P., & Mangelsdorf, D. J. (2001). Four faces of liver X receptor: star, sensor, regulator, and therapeutic target. Proceedings of the National Academy of Sciences, 98(20), 11164-11166. doi:10.1073/pnas.191390798
[3] Metacrine. (n.d.). Pipeline. Retrieved from https://www.metacrine.com/pipeline
[4] Novo Nordisk A/S. (n.d.). Patent Portfolio. (Information derived from public patent databases and company disclosures regarding LXR research).
[5] Pfizer Inc. (n.d.). Patent Portfolio. (Information derived from public patent databases and company disclosures regarding LXR research).
[6] University of Michigan. (n.d.). Technology Transfer Portfolio. (Information derived from public patent databases and university technology licensing disclosures related to LXR research).
[7] Li, H., Lu, Z., & Xu, H. (2017). Liver X Receptor Agonists: Emerging Therapeutic Targets for Cardiovascular Diseases. Current Pharmaceutical Design, 23(42), 6396-6408. doi:10.2174/1381612823666170727120903
More… ↓
⤷ Start Trial
|
